Dergiler / Black Sea Journal of Health Science / 2022 / Cilt: 5 - Sayı: 1

Oral Candidiasis as a Local Adverse Effect of Inhaled Corticosteroids: What the Dental Practitioner Should Know

Sayfa
107–115
Yayın Tarihi
2022-01-01
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Understanding the factors leading to increased risk can give the opportunity of focusing on the patients who need timely intervention.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Inhaled corticosteroids are increasingly recommended at all stages of asthma in all age groups as a first-line treatment for controlling symptoms and minimizing oral corticosteroid dependence in chronic asthma owing to their anti-inflammatory and immunosuppressive effects.
📊
Temel Bulgular & Veri:Despite the fact that they are highly effective, their use can be accompanied by systemic and local adverse effects.
💡
Sonuç & Katkı:Understanding the factors leading to increased risk can give the opportunity of focusing on the patients who need timely intervention.
🔬Tür:Literatür & Derleme Çalışması
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Corticosteroid · Inhaler · Local adverse effects

Abstract

Inhaled corticosteroids are increasingly recommended at all stages of asthma in all age groups as a first-line treatment for controlling symptoms and minimizing oral corticosteroid dependence in chronic asthma owing to their anti-inflammatory and immunosuppressive effects. Despite the fact that they are highly effective, their use can be accompanied by systemic and local adverse effects. Systemic adverse effects are infrequent, but oral candidiasis, the most common oral fungal infection, is a frequently observed local adverse effect of inhaled corticosteroid use. This adverse effect may lead to discomfort and cause reduced patient compliance. In this review, clinical findings of oral candidiasis, potential pathogenity mechanisms following such therapy along with the specific prophylactic measures that should be undertaken to minimize this adverse effect are discussed extensively. Understanding the factors leading to increased risk can give the opportunity of focusing on the patients who need timely intervention.

🔖

Bu Makaleye Atıf Yap

GÜMRÜ, B., AKKİTAP, M. P. (2022). Oral Candidiasis as a Local Adverse Effect of Inhaled Corticosteroids: What the Dental Practitioner Should Know. Black Sea Journal of Health Science, Cilt: 5 - Sayı: 1, 107–115. https://ajindex.com/articles/745259

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (11)

  1. Baptist AP, Reddy RC. 2009. Inhaled corticosteroids for asthma: are they all the same? J Clin Pharm Ther, 34(1): 1-12.
  2. Barkvoll P, Attramadal A. 1989. Effect of nystatin and chlorhexidine digluconate on Candida albicans. Oral Surg Oral Med Oral Pathol, 67(3): 279-281.
  3. Barnes PJ, Adcock IM. 2003. How do corticosteroids work in asthma? Ann Intern Med, 139(5 Pt 1): 359-370. Buhl R. 2006. Local oropharyngeal side effects of inhaled corticosteroids in patients with asthma. Allergy, 61(5): 518-526.
  4. Buttini F, Miozzi M, Balducci AG, Royall PG, Brambilla G, Colombo P, Bettini R, Forbes B. 2014. Differences in physical chemistry and dissolution rate of solid particle aerosols from solution pressurised inhalers. Int J Pharm, 465(1-2): 42-51.
  5. Cates CJ, Bestall J, Adams N. 2006. Holding chambers versus nebulisers for inhaled steroids in chronic asthma. Cochrane Database Syst Rev, 1: CD001491. Cheng T, Yong L, Zhang H, Chen L, Tu J, Hui X, Cheng Q, Wan H. 2017. Incidence of oral candidiasis is associated with inhaled corticosteroids in Chinese patients: a systematic review and meta-analysis. Int J Clin Exp Med, 10(3): 5546-5560. Dahl R. 2006. Systemic side effects of inhaled corticosteroids in patients with asthma. Respir Med, 100(8): 1307-1317.
  6. Dekhuijzen PNR, Batsiou M, Bjermer L, Bosnic-Anticevich S, Chrystyn H, Papi A, Rodríguez-Roisin R, Fletcher M, Wood L, Cifra A, Soriano JB, Price DB. 2016. Incidence of oral thrush in patients with COPD prescribed inhaled corticosteroids: effect of drug, dose, and device. Respir Med, 120: 54-63.
  7. Dennis M, Itkin IH. 1964. Effectiveness and complications of aerosol dexamethasone phosphate in severe asthma. J Allergy, 35: 70-76.
  8. Derendorf H, Nave R, Drollmann A, Cerasoli F, Wurst W. 2006. Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma. Eur Respir J, 28(5): 1042-1050. Derendorf H. 1997. Pharmacokinetic and pharmacodynamic properties of inhaled corticosteroids in relation to efficacy and safety. Respir Med, 91(Suppl A): 22-28.
  9. Ellepola AN, Samaranayake LP. 2001. Inhalational and topical steroids, and oral candidosis: a mini review. Oral Dis, 7(4): 211-216.
  10. Epstein JB, Komiyama K, Duncan D. 1986. Oral topical steroids and secondary oral candidiasis. J Oral Med, 41(4): 223-227, 273. Erdoğan T, Karakaya G, Kalyoncu AF. 2019. The frequency and risk factors for oropharyngeal candidiasis in adult asthma patients using inhaled corticosteroids. Turk Thorac J, 20(2): 136-139.
  11. Fukushima C, Matsuse H, T